IMRX - Immuneering Corporation
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
IMRX price evolution
IMRX
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0 | |||
| Inventory | ||||
| Total current assets | $89.08 | $100.6 | $111.51 | $94.23 |
| Long term investments | ||||
| Property, plant & equipment | $5.4 | $5.5 | $5.56 | $5.63 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $102.58 | $113.9 | $124.9 | $107.7 |
| Current liabilities | ||||
| Accounts payable | $2.11 | $1.9 | $2.69 | $2.72 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $7.85 | $5.6 | $5.48 | $5.53 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $12.01 | $9.9 | $9.79 | $9.91 |
| Shareholders' equity | ||||
| Retained earnings | -$163.26 | -$148.2 | -$135.58 | -$123.39 |
| Other shareholder equity | -$0 | -$0 | $0 | |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.01 | $0.25 | $0.5 | |
| Inventory | ||||
| Total current assets | $89.08 | $108.75 | $152.33 | $37.73 |
| Long term investments | ||||
| Property, plant & equipment | $5.4 | $5.78 | $6.13 | $0.68 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $102.58 | $122.37 | $166.7 | $38.42 |
| Current liabilities | ||||
| Accounts payable | $2.11 | $3.15 | $1.39 | $1.48 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $7.85 | $8.05 | $5.63 | $2.26 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $12.01 | $12.52 | $10.72 | $2.8 |
| Shareholders' equity | ||||
| Retained earnings | -$163.26 | -$109.79 | -$59.27 | -$25.74 |
| Other shareholder equity | -$0 | -$0.03 | -$0.05 | |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 29 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.04 | $0.09 | $0.18 | $0.19 |
| Cost of revenue | ||||
| Gross Profit | $0.02 | $0.05 | $0.09 | -$0.02 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $13.21 | $11.69 | $13.02 | $11.1 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.31 | |||
| Interest expense | $0.22 | $0.14 | $0.13 | $0.14 |
| Net income | ||||
| Net income | -$12.84 | -$11.53 | -$12.9 | -$10.78 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.08 | $2.31 | $1.92 | |
| Cost of revenue | ||||
| Gross Profit | $0.93 | $1.03 | $0.7 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $34.81 | $18.11 | $6.99 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.31 | |||
| Interest expense | $0.17 | $0.04 | -$0.29 | |
| Net income | ||||
| Net income | -$33.54 | -$17.04 | -$7.71 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 29 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $33.68 | $34.56 | $12.4 | -$75.62 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $0.2 | $0.22 | $0.19 | $144.26 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $1.53 | $13.05 | $0.32 | $37.8 |
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$75.62 | -$0.05 | -$0.02 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $144.26 | $37.98 | $17.17 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $37.8 | $23.31 | $12.71 | |
News
Fundamentals
| Market cap | $42.44M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 29.27M |
| Revenue | $506.09K |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$48.05M |
| Revenue Q/Q | -92.04% |
| Revenue Y/Y | -87.96% |
| P/E ratio | -0.88 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 83.87 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.64 |
|---|---|
| ROA | -42.80% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 11.35 |
| Quick ratio | N/A |